Reprogrammed Fat Cells Offer New Hope for Type 1 Diabetes Treatment
Scientists in China have successfully used reprogrammed fat cells, known as chemically induced pluripotent stem-cell-derived islets (CiPSCs), to treat a patient with type 1 diabetes, eliminating the need for insulin 75 days post-procedure. This innovative approach, detailed in the journal Cell, has shown lasting effects one year later, prompting calls for further clinical studies. The treatment's success could potentially revolutionize diabetes care, though its adoption in the U.S. remains uncertain due to regulatory hurdles.